

## **New Bio-Facilities Planned**

**Biogen** announces plans for a new USD \$1 BIL biopharma manufacturing facility in Luterbach, Switzerland. The facility will have 400 staff. *Source: FiercePharmaManufacturing, Q4 2015*

**Novo Nordisk A/S** is constructing a USD \$1.2 BIL bioprocessing facility in Clayton, North Carolina, USA, for manufacture of semaglutide (GLP-1) and other current and future Novo insulin products. *Source: FiercePharma, Q4 2015*

**Genovate Biotechnology (Changzhou, Taiwan)** started construction of its new 72,000 sq. ft. Insulin Ecological Industrial Park in Changzhou National Hi-tech District, China. Genovate plans to be the largest insulin manufacturer in China and 4<sup>th</sup> worldwide, producing 10 tons and 1 billion doses annually. *Source: BioSpectrum, Q4 2015*

**BioCity (Nottingham, UK)** is adding a USD \$47 MIL facility to house life science start-ups including CROs. A second 50,000 sq. ft. building is due for completion in 2017. *Source: Outsourcing-Pharma.com; Q4 2015*

**Jiangsu Hengrui Medicine (Lianyungang, Jiangsu Province, China)** is investing USD \$240 MIL to build an internationally compliant biopharmaceutical production facility. Several months ago, Hengrui announced plans to spend \$137 million building a new biologic drug manufacturing facility in Suzhou. *Source: ChinaBioToday, Q4 2015*

**Hoffmann-La Roche** is building new headquarters in Basel, Switzerland. The new 41-story building will be the tallest building in Switzerland, and visible from France and Germany. *Source: Pharmaceutical Manufacturing, Q4 2015*

**UK Cell Therapy Catapult** program is constructing a USD \$87 MIL large-scale cellular therapies manufacturing plant in Stevenage, UK. *Source: BioPharma-Reporter.com, Q4 2015*

**China Gateway Biologics (Shanghai, China)**, CMO subsidiary of ShangPharma, is building a USD \$60 MIL biopharma single-use manufacturing facility in Qidong, China, with a 500 L and two 2,000 L commercial manufacturing process lines targeted to meet Western GMP standards. *Source: FiercePharmaManufacturing, Q4 2015*

**Bluebird Bio (Cambridge, Massachusetts, USA)** will be moving to new 230,000 sq. ft. facilities in Cambridge later this year. New Genzyme facilities will be its neighbor. *Source: Boston Business Journal, Q4 2015*

**Vetter GmbH (Germany)**, a major fill-finish CMO, will invest 300 MIL euros to expand and upgrade its manufacturing facilities over an estimated five-year period. New facilities will make extensive use of restricted access barrier systems (RABS). *Source: Vetter PR, Q4 2015*

**BeiGene (Beijing, China)** is building a 9,000 sq. meter biopharma commercial manufacturing facility in Suzhou, China, targeted to meet Western GMP standards. *Source: Outsourcing-Pharma.com, Q4 2015*

**MasterPlasma (Sweden)** is building a USD \$76 MIL blood plasma products plant in Vladmir, Russia, with capacity of 600,000 L/year using purification technology licensed from Prometic Life Sciences (Canada). KeyPlants (Sweden) is overseeing design and engineering. *Source: Outsourcing-Pharma.com, Q4 2015*

**Novo Nordisk A/S** is building a USD \$78.4 MIL facility in Iran for manufacture of insulin pens; the first major investment by a Western pharma co. since recent lifting of trade sanctions on Iran. *Source: Financial Times, Q4 2015*

**Austin Community College (Austin, Texas, USA)** is building a center for training bioprocessing technicians with funding from the National Science Foundation (NSF). *Source: BioPharma-Reporter.com, Q4 2015*

**Eli Lilly** is adding 6,000 sq. ft. to its planned 17,000 sq. ft. Lilly Cambridge Innovation Center R&D facility in Cambridge, Massachusetts, USA. *Source: FierceBiotech, Q4 2015*

## **New Facilities Completed**

**AstraZeneca (MedImmune)** bought a 300,000 sq. ft. former Amgen manufacturing facility in Boulder, Colorado, USA. Reopening in 2017, the facility will have 400 staff and will double the co.'s USA biopharma manufacturing capacity. *Source: FiercePharmaManufacturing, Q4 2015*

**Clariant** officially opened its new 6,000 sq. ft. Clariant Biotech Centre (CBC) near Munich. The facility will specialize in industrial bioprocessing R&D. *Source: Specialty Chemicals Magazine, Q4 2015*

**Sandoz/Novartis** opened its new BioInject plant in Schafftenau, Austria to manufacture autoinjectors and prefilled syringes for Sandoz/Novartis' biosimilars and other biopharmaceuticals. *Source: FiercePharmaManufacturing, Q4 2015*

**IDT Biologika GmbH** formally opened its upgraded vaccine R&D and manufacturing facilities in Rockville, Maryland, USA (from acquisition of Aeras facilities). *Source: Pharmaceutical Outsourcing, Q4 2015*

**Intertek (Manchester, UK)**, a bioanalytical CRO, opened its new 10,000 sq. ft. facility for biosimilars-related analysis. The new lab. mirrors the company's lab. in San Diego, California, USA. *Source: Outsourcing-Pharma.com, Q4 2015*

**Alexandria LaunchLabs** is a new biotech incubator facility in Gaithersburg, Maryland, USA. *Source: BioHealth Innovation, Q4 2015*

**Biocon (India)** opened an insulin injector manufacturing facility in Bungaluru, India. *Source: Economic Times, Q4 2015*

## **BioINNOVATIONS**

**Lonza AG** expanded its cellular therapy capabilities, particularly, for handling human mesenchymal stem cells (hMSCs), and is now selling 3 types of hMSCs. *Source: Outsourcing-Pharma.com, Q4 2015*

**The National University of Singapore (NUS)** started a new research initiative called the NUS Synthetic Biology for Clinical and Technological Innovation (SynCTI) to develop research capacity and capabilities in synthetic biology. *Source: BioSpectrum, Q4 2015*

## **BioNEWS**

A 690,000 sq. ft. Sanofi facility in Kansas City, Missouri, USA, that currently manufactures a variety of pharmaceutical products is for sale. *Source: FiercePharma email, Q4 2015*

**Baxalta (spun-off from Baxter)** is selling the 215,000 sq. ft. Brooklyn Park, Minnesota, USA, former Genmab bioprocessing facility it acquired in 2013, and now plans to outsource its bioprocessing. *Source: Biopharma-Reporter.com, Q4 2015*

**Abzena plc (Cambridge, UK)** acquired PacificGMP (San Diego, California, USA), a biopharma CMO specializing in single-use bioprocessing. *Source: Abzena PR, Q4 2015*

**GE** extended its purification product lines and will be marketing membrane absorbers from Sartorius Stedim under its own brand. *Source: Biopharma-Reporter.com, Q4 2015*

**GSK** is closing its R&D facilities in Les Ultes, France, and consolidating its R&D in the UK and USA. GSK will retain its current manufacturing facilities in France. *Source: In-PharmaTechnologist.com, Q4 2015*

**IDT Biologika (Germany)** acquired Gallant Custom Laboratories, based in Ontario, Canada, a veterinary vaccines manufacturer. *Source: IDT Biologika PR, Q4 2015*